Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.

Dermatology 2013 23;227(4):353-60. Epub 2013 Nov 23.

Competence Center Chronic Pruritus, Department of Dermatology, University Hospital of Münster, Münster, Germany.

Background: In the treatment of atopic dermatitis, pimecrolimus has high antipruritic effects.

Objective: To investigate the efficacy of 1% pimecrolimus cream in comparison to 1% hydrocortisone cream in non-atopic prurigo nodularis (PN).

Methods: A randomized, controlled, double-blind study with intraindividual randomization was done in 30 patients (17 females, 13 males; mean age 58.5 years) with PN.

Results: Pruritus intensity decreased significantly (p < 0.001) on both treated sides as early as after 10 days of treatment; scratch lesions improved (p < 0.001). Quality of life as assessed by the Dermatology Life Quality Index improved significantly. However, a significant advantage of pimecrolimus over hydrocortisone was not found.

Conclusion: The results suggest that the non-steroid pimecrolimus is an effective alternative for PN treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000355671DOI Listing
September 2014

Publication Analysis

Top Keywords

prurigo nodularis
8
non-atopic prurigo
8
pimecrolimus
5
age 585
4
0001 treated
4
males age
4
treated sides
4
585 years
4
years pnresults
4
intensity decreased
4
pruritus intensity
4
females males
4
pnresults pruritus
4
decreased 0001
4
patients females
4
pnmethods randomized
4
nodularis pnmethods
4
cream non-atopic
4
hydrocortisone cream
4
randomized controlled
4

Similar Publications